What is the incidence rate of central serous chorioretoucher retinopathy (Central Serous Chorioretoucher Retinopathy) ?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The incidence rate of central serous chorioretinopathy (CSC) is approximately 34.0 per 100,000 person-years in the general population, with a significantly higher incidence in men (54.2 per 100,000 person-years) compared to women (15.7 per 100,000 person-years) 1. This condition is characterized by fluid accumulation under the retina, leading to visual disturbances including blurred vision, distorted vision, and reduced color perception.

Key Points

  • The incidence of CSC varies by gender, with men being nearly 3.5-fold more likely to develop the condition than women 1.
  • The condition typically affects individuals between 30 and 50 years of age.
  • Risk factors for CSC include stress, corticosteroid use, type A personality traits, and elevated cortisol levels.
  • Most cases of CSC resolve spontaneously within 3-6 months without treatment, though some patients may require interventions such as photodynamic therapy, anti-VEGF injections, or mineralocorticoid receptor antagonists like eplerenone or spironolactone if the condition persists.
  • Recurrence rates are significant, with approximately 30-50% of patients experiencing at least one recurrence within the first year after initial resolution.

Diagnosis and Treatment

  • Multimodal imaging modalities, including OCT, FA, ICGA, and FAF, are important for establishing a diagnosis of CSC, as many other conditions can mimic CSC 1.
  • The presence of SRF, as well as increased choroidal thickness, serous PEDs, and dilated choroidal veins, can be evaluated using OCT.
  • Recent studies have shown the superiority of half-dose photodynamic therapy (PDT) over high-density subthreshold micropulse laser treatment and non-superiority of the oral mineralocorticoid receptor (MR) antagonist eplerenone treatment compared to placebo 1.

From the Research

Incidence Rate of Central Serous Chorioretinopathy

  • The incidence rate of central serous chorioretinopathy (CSCR) is estimated to be around 10 per 100,000 in men, with CSCR occurring six times more commonly in men compared to women 2.
  • The disease predominantly affects men between 30 and 50 years of age 3, 4.
  • CSCR is characterized by retinal serous detachment, usually localized in the macular region, and can be acute or chronic 3, 4, 5.

Epidemiology and Risk Factors

  • The annual incidence rate of CSCR is reported to be 10 per 100,000 in men 2.
  • Risk factors for CSCR include systemic corticosteroid use, type A personality, pregnancy, and endogenous Cushing's syndrome 2.
  • The disease can be precipitated by psychosocial stress and hypercortisolism 4.

Natural Course and Treatment

  • Most acute CSCR cases resolve spontaneously within 2-3 months 2.
  • The natural course of the disease is usually self-limiting, with spontaneous resolution and total fluid reabsorption 5.
  • Treatment options include observation, conventional laser treatment, subthreshold laser treatment, photodynamic therapy, and treatment with mineralocorticoid receptor antagonists and anti-vascular endothelial growth factor drugs 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Central Serous Chorioretinopathy - an Overview.

Klinische Monatsblatter fur Augenheilkunde, 2021

Research

Central serous chorioretinopathy.

Acta ophthalmologica, 2008

Research

Central Serous Chorioretinopathy: An Update on the Current State of Management.

Klinische Monatsblatter fur Augenheilkunde, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.